Welcome to our dedicated page for Ayala Pharm news (Ticker: ADXS), a resource for investors and traders seeking the latest updates and insights on Ayala Pharm stock.
Ayala Pharmaceuticals (ADXS) is a clinical-stage biotech company pioneering novel cancer immunotherapies and small molecule treatments targeting rare tumors and aggressive cancers. This dedicated news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Our curated collection features official press releases, trial result announcements, and expert analyses of ADXS's proprietary bacterial-based immunotherapy platform. Key focus areas include advancements in modifying the tumor microenvironment, progress across the company's oncology pipeline, and collaborations advancing next-generation cancer therapies.
Users can expect comprehensive coverage of:
• Clinical trial updates for immunotherapy candidates
• Strategic partnership announcements with biopharma leaders
• Regulatory developments across global markets
• Scientific presentations at major oncology conferences
Bookmark this page for verified updates on Ayala Pharm's progress in developing treatments that harness the immune system to combat challenging cancers. Check regularly for new insights into their dual-platform approach combining bacterial vectors and targeted small molecules.
Ayala Pharmaceuticals announced a poster presentation at the 2023 ASCO Annual Meeting, showcasing updated results from the Phase 2 portion of the RINGSIDE study evaluating AL102 for desmoid tumors. The presentation will take place on June 3, 2023, featuring findings from a clinical trial aimed at treating rare connective tissue tumors. The session will be led by Mrinal M. Gounder from the Memorial Sloan Kettering Cancer Center. This study is part of a larger Phase 2/3 trial assessing AL102’s efficacy on desmoid tumors, with a global patient enrollment strategy. Desmoid tumors are rare, with no FDA-approved systemic therapies currently available for challenging cases. AL102 is an investigational therapy designed to inhibit Notch signaling pathways.
Ayala Pharmaceuticals (OTCQX: ADXS) announced positive interim results from its Phase 2/3 RINGSIDE study for AL102, an investigational drug for desmoid tumors. The Independent Data Monitoring Committee (IDMC) recommended continuing the study without modifications, allowing for global patient enrollment in Phase 3. The primary endpoint is progression-free survival (PFS), with key secondary measures including objective response rate (ORR). The company plans to present updated Phase 2 data at a medical meeting in 2023. AL102 aims to address an urgent medical need as no FDA-approved systemic therapies currently exist for progressive desmoid tumors.
Ayala Pharmaceuticals, previously Advaxis Inc., reported its fiscal 2022 results, with revenues dropping to $250,000 from $3.2 million in 2021. The company closed its merger with Old Ayala in January 2023. As of October 31, 2022, cash and cash equivalents stood at $25.2 million. The net loss for the year was approximately $14.4 million, improving from a $17.9 million loss in 2021. Key priorities include advancing the RINGSIDE study of AL102 for desmoid tumors and gaining clarity on the development path of AL101 in recurrent adenoid cystic carcinoma. AL102 received Fast Track designation from the FDA, enhancing its development prospects.
Advaxis announced the completion of its merger with Ayala Pharmaceuticals, effective January 19, 2023. The combined entity will operate under the name Ayala Pharmaceuticals, primarily focused on the development of AL102 for treating desmoid tumors. Advaxis will retain its stock symbol ADXS on OTC, with plans to uplist to Nasdaq, though success is not guaranteed. The management team includes Kenneth Berlin as CEO and a board comprising experienced members from both companies. The merger aims to enhance development capabilities for oncology therapeutics, particularly targeting rare cancers.
